- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 47
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1 Infection
- Interventions
- F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF, NRTIs, Third Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
- Conditions
- HIV-1-Infection
- Interventions
- ISL/LEN, Antiretroviral Combinations
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- COBI, DRV, NRTIs
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more
- Conditions
- HIV/AIDS
- Interventions
- Darunavir/Cobicistat, Dolutegravir
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Stanford, California • Aurora, Colorado
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- DRV/COBI FDC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Immunodeficiency Virus Type 1, Human
- Interventions
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- PI, RTV, FTC/TDF, Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more
- Conditions
- Human Immunodeficiency Virus - Type 1
- Interventions
- Darunavir (DRV), Ritonavir (rtv)
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- BMS-663068, Darunavir, Cobicistat
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more
- Conditions
- HIV Infection
- Interventions
- Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir, Ritonavir, Atazanavir
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,814 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Symtuza
- Drug
- Lead sponsor
- Midland Research Group, Inc.
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Oakland Park, Florida
- Conditions
- HIV-1
- Interventions
- Etravirine (TMC125), Optimized background regimen (OBR)
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
- Conditions
- HIV-1 Infection
- Interventions
- RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
- Conditions
- HIV Infections
- Interventions
- Tipranavir, Darunavir, Ritonavir
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • Fort Lauderdale, Florida • Miami, Florida + 5 more
- Conditions
- HIV-1 Infection
- Interventions
- darunavir, ritonavir, zidovudine, lamivudine, abacavir
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- HIV
- Interventions
- Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
- Conditions
- Healthy
- Interventions
- Darunavir (DRV), Cobicistat (COBI), Emtricitabine (FTC), Tenofovir Alafenamide (TAF)
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
- Conditions
- HIV, Tuberculosis
- Interventions
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
- Conditions
- HIV Infections
- Interventions
- ATV/r, DRV/r
- Drug
- Lead sponsor
- Community Research Initiative of New England
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 7 more